Free tool
FAERS Monitor: Daxxify
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761127 or its brand name (Daxxify, Daxibotulinumtoxina-Lanm). Reports on generic versions are filed under their own applications.
Reports
5,969
Serious
5,181
87% of reports
Hospitalization
2,323
Death reported
1,844
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use2,430
- drug ineffective1,941
- drug intolerance1,370
- product use in unapproved indication1,345
- headache1,188
- migraine1,122
- nausea1,111
- hypoaesthesia1,018
- maternal exposure during pregnancy981
- pain962
- hypertension934
- dizziness916
- gastrooesophageal reflux disease915
- epilepsy899
- blepharospasm860
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 7 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 31 |
| 2009 | 46 |
| 2010 | 42 |
| 2011 | 94 |
| 2012 | 562 |
| 2013 | 13 |
| 2014 | 11 |
| 2015 | 12 |
| 2016 | 16 |
| 2017 | 24 |
| 2018 | 55 |
| 2019 | 138 |
| 2020 | 229 |
| 2021 | 470 |
| 2022 | 491 |
| 2023 | 560 |
| 2024 | 1,059 |
| 2025 | 1,340 |
| 2026 | 758 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,190 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blepharospasmSignal | 860 | 556.9 | 520.7 | 411,801 |
| epilepsySignal | 899 | 106.7 | 100.4 | 91,416 |
| drug intoleranceSignal | 1,370 | 50.7 | 48.4 | 66,023 |
| migraineSignal | 1,122 | 41.9 | 39.7 | 44,425 |
| gastrooesophageal reflux diseaseSignal | 915 | 40.5 | 38.1 | 34,943 |
| maternal exposure during pregnancySignal | 981 | 39.2 | 37.0 | 36,238 |
| hypoaesthesiaSignal | 1,018 | 24.1 | 22.8 | 22,547 |
| product use in unapproved indicationSignal | 1,345 | 19.2 | 18.3 | 23,364 |
| hypertensionSignal | 934 | 15.6 | 14.7 | 12,824 |
| off label useSignal | 2,430 | 9.8 | 9.5 | 19,979 |
| headacheSignal | 1,188 | 6.7 | 6.4 | 5,906 |
| dizzinessSignal | 916 | 6.5 | 6.1 | 4,336 |
| painSignal | 962 | 5.5 | 5.2 | 3,662 |
| drug ineffectiveSignal | 1,941 | 5.2 | 5.0 | 7,001 |
| nauseaSignal | 1,111 | 5.0 | 4.7 | 3,632 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.